Vnitr Lek 2024, 70(2):84-90 | DOI: 10.36290/vnl.2024.018

Arterial hypertension in metabolic syndrome, 2024

Barbora Nussbaumerová, Hana Rosolová

Centrum preventivní kardiologie, Univerzita Karlova, Lékařská fakulta v Plzni, 2. interní klinika Fakultní nemocnice Plzeň

Metabolic syndrome is a cluster of cardiometabolic risk factors. The diagnosis includes elevated blood pressure (BP), elevated plasma glucose, dyslipidemia (elevated triglycerides and low HDL-cholesterol) and abdominal overweight or obesity. Lifestyle changes are essential in the treatment of MS. Hypertension is defined as office systolic BP values ≥ 140 mm Hg and/or diastolic BP values ≥ 90 mm Hg which are also borderline values to iniciate drug treatment. Lowering blood pressure can substantially reduce premature morbidity and mortality. Provided that the treatment is well tolerated, treated BP values should be targeted to 130/80 mm Hg or lower in most patients, although in some groups the evidence is less compelling. In older patients (> 65 years), systolic BP should be targeted to between 130 and 140 mm Hg, Treated BP should not be targeted below120/70 mm Hg. An early compensation is essential to prevent target organ damage. A preferable (fixed) combination are ACEi or angiotensin receptor blockers with calcium channel blockers and/or metabolically neutral diuretics.

Keywords: arterial hypertension, metabolic syndrome, renin-angiotensin-aldosteron system, sympathetic nervous system, target values, healthy lifestyle, pharmacotherapy, cardiovascular risk.

Accepted: March 26, 2024; Published: April 10, 2024  Show citation